ArticleScientific reports2014
Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04907877 (Role of Nutritional Support With Probiotics in Adult Outpatients With Symptomatic COVID-19), which is not on this map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Nutritional Support With Probiotics in Adult Outpatients With Symptomatic COVID-19: a Randomized Dietary Study
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Trends and hotspots in global influenza and intestinal flora research based on bibliometrics.Frontiers in microbiology · 2025Pooled it
- Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies.European journal of nutrition · 2021Pooled it
- Role of Probiotics in Stimulating the Immune System in Viral Respiratory Tract Infections: A Narrative Review.Nutrients · 2020Pooled it
- Correlation between plasmacytoid dendritic cell activation and suppression of subjective physical symptoms followingFrontiers in nutrition · 2025Trial
- Trial
- Lactic Acid Bacteria with Probiotic Potential Regulating Macrophages: Mechanisms, Regulatory Features, and Clinical Applications.Probiotics and antimicrobial proteins · 2026Review
- Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence.Viruses · 2026Review
- Article
- The Therapeutic Effect and Mechanism ofJournal of microbiology and biotechnology · 2025Article
- The pulmonary commensal Lactobacillus regulated lung γδ T cells to enhance resistance against bacterial infections.Microbiome · 2025Article
- Oral Administration of Limosilactobacillus reuteri KBL346 Ameliorates Influenza Virus A/PR8 Infection in Mouse.Probiotics and antimicrobial proteins · 2025Article
- Exploring the Therapeutic Landscape of Probiotics in Enteric and Respiratory Viral Infections.Probiotics and antimicrobial proteins · 2025Review
- DNA fromMicroorganisms · 2025Article
- Lactobacillus johnsonii JERA01 activates macrophages and increases Th-1 T cell population in mouse small intestine.PloS one · 2025Article
- Modulation of the Gut-Lung Axis by Water Kefir and Kefiran and Their Impact on Toll-like Receptor 3-Mediated Respiratory Immunity.Biomolecules · 2024Article
- Review
- A Probiotic Bacterium with Activity against the Most Frequent Bacteria and Viruses Causing Pediatric Diarrhea:Microorganisms · 2024Review
- The Sdp-SH3b2 domain contained inFrontiers in immunology · 2024Article
- Article
- The Effect ofMicroorganisms · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Lactobacillus gasseri SBT2055 (LG2055) is a probiotic lactic acid bacterium with properties such as bile tolerance and ability to improve the intestinal environment. In this study, we established that the oral administration of LG2055 exhibits efficacy to protect mice infected with the influenza virus A/PR8. The body weight losses were lower with the LG2055 administration after the PR8 virus infection. At 5 days after the infection, the virus titer was significantly decreased as was the amount of produced IL-6 in the lung tissue, the number of total cells in the bronchoalveolar lavage fluid was reduced by the LG2055 administration. The expression of the Mx1 and Oas1a genes, critical for the viral clearance in the lung tissues was increased by the pre-treatment with LG2055. These findings suggest that the LG2055 administration is effective for the protection against influenza A virus infection by the down-regulation of viral replication through the induction of antiviral genes expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.